For a patient with a metastatic solid tumor in remission on a checkpoint inhibitor who also has R/R multiple myeloma, would you feel comfortable with a bispecific T-cell engager antibody?

This is rare but I've seen it twice last year! One with melanoma on nivolumab and one with lung cancer on pembrolizumab (both cases in deep remission), both with difficult-to-control multiple myeloma who qualify for a bispecific antibody like teclistamab. Would you be willing to use PD-1 inhibition and BCMAxCD3 targeting together?

Answer from: Medical Oncologist at Academic Institution

The short history of checkpoint inhibitors in myeloma has raised some issues with their use. Of course, in this scenario, they are being employed for other cancers, but they may be instructive nonetheless, especially as it pertains to combination strategies. IMiDs and checkpoint inhibitors do...

Comments

Medical Oncologist at University of Washington, Fred Hutchinson Cancer Research Center
This is genuinely very helpful, @Ben - thank you!!...

Medical Oncologist at Winship Cancer Institute of Emory University
Comprehensive, clear, and actionable. Thanks!

Please select the option that best describes you:

For a patient with a metastatic solid tumor in remission on a checkpoint inhibitor who also has R/R multiple myeloma, would you feel comfortable with a bispecific T-cell engager antibody?

Related Questions